Levosert One (Levonorgestrel)

Levosert One, containing levonorgestrel, is used within the hormonal contraceptive pathway for preventing pregnancy.

• Contraception: provides continuous pregnancy prevention for up to five years of use, eliminating the need for daily pills.
• Menstrual bleeding reduction: may decrease the volume and duration of menstrual bleeding, helping women with heavy periods.
• Endometrial protection: creates a hostile environment that prevents implantation of a fertilized egg, contributing to contraceptive efficacy.
• User convenience: requires only a single insertion by a qualified provider, reducing the need for frequent clinic visits.

• Levonorgestrel released from the intrauterine system acts locally on the endometrium and cervical mucus. It binds to progesterone receptors, causing the cervical mucus to become thick and impermeable to sperm, suppresses the mid‑cycle luteinizing hormone surge to inhibit ovulation, and induces endometrial atrophy, thereby preventing implantation. The high local concentration minimizes systemic exposure, allowing effective contraception with a favorable safety profile.

Levosert One may be associated with a range of adverse reactions. Most users experience mild, transient effects that typically resolve without intervention, while rare serious events require medical attention.

Common Side Effects

• Irregular vaginal bleeding, especially during the first months after insertion
• Amenorrhea (absence of menstrual periods) after several months of use
• Pelvic or lower abdominal pain that may be mild to moderate
• Headache, often transient and responsive to simple analgesics

Serious or Rare Side Effects

• Uterine perforation, a rare event that may require surgical management
• Device expulsion, where the IUS partially or completely exits the uterine cavity
• Ectopic pregnancy, a rare pregnancy occurring outside the uterus despite device use

Before prescribing Levosert One, clinicians should consider several precautionary measures to ensure safe and effective use.

• Pregnancy testing: confirm the patient is not pregnant prior to insertion.
• Uterine anomalies: evaluate for fibroids, septum or other structural abnormalities that may affect placement.
• Active infection: screen for pelvic inflammatory disease and treat any infection before device insertion.
• Bleeding disorders: assess coagulation status and advise caution in patients with thrombocytopenia or anticoagulant therapy.
• Device monitoring: schedule follow‑up visits to verify correct IUS position and address any symptoms.
• Store at room temperature: keep the device in its original packaging, protect from moisture and direct sunlight.

Levosert One can interact with other medicines that affect hormone levels or hepatic metabolism.

Major Interactions (Avoid)

• Enzyme inducers: drugs such as rifampin, carbamazepine, phenytoin may lower levonorgestrel effectiveness.
• Antifungal azoles: ketoconazole and itraconazole can increase systemic levonorgestrel levels and risk of side effects.

Moderate Interactions (Monitor Closely)

• Antibiotics: some, like tetracycline, may slightly reduce contraceptive efficacy.
• Antiepileptics: valproic acid and lamotrigine may require monitoring of hormonal effects.
• Herbal supplements: St. John’s wort may induce metabolism and diminish contraceptive protection.
• Hormonal therapies: concurrent use of other progestins or estrogen may lead to additive hormonal effects.